Skip to search formSkip to main contentSkip to account menu

AN 207

Known as: AN-207 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

DoxorubicinGonadorelin
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone‐releasing hormone analog AN‐207
Receptors for luteinizing hormone‐releasing hormone (LHRH) on human prostate cancers can be used for targeted chemotherapy with… 
2005
2005
Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
Cytotoxic analogue of luteinizing hormone releasing hormone (LHRH), AN-207, binds with high affinity to LHRH receptors and can be… 
2002
2002
Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207
The receptors for luteinizing hormone-releasing hormone (LHRH) are found in 80% of human ovarian carcinomas. These receptors can… 
2001
2001
In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses
Targeting of cytotoxic agents represents a modern approach to the treatment of various cancers, that improves the efficacy and… 
2000
2000
Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
A highly potent derivative of doxorubicin, 2-pyrrolinodoxorubicin (AN-201), was linked to [D-Lys6]luteinizing hormone-releasing… 
2000
2000
Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice
Receptor targeted chemotherapy is less toxic and more effective than conventional chemotherapy. Receptors for luteinizing hormone… 
1999
1999
Complete regression of MX‐1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone–releasing hormone, AN‐207
Receptors for luteinizing hormone–releasing hormone (LH‐RH) are found in about 50% of human breast carcinomas. A highly potent… 
1999
1999
Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone.
The selectivity of ligands specific for certain cells can be used to preferentially target chemotherapeutic compounds to… 
1999
1999
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
1997
1997
Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing…
Tumor inhibitory action and the optimal dosage regimens of highly potent targeted cytotoxic luteinizing hormone releasing hormone… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)